PCI Biotech : Notice AGM 2023

To the shareholders of PCI Biotech Holding ASA

NOTICE OF ANNUAL GENERAL MEETING OF PCI BIOTECH HOLDING ASA

Notice is hereby served that the annual general meeting of PCI Biotech Holding ASA, reg.no.: 991 036 393 (the “Company“) will be held on 25 May 2023 at 10:00 hours CEST at meeting room #3, 3rd floor, entrance 2A Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, 0379 Oslo, Norway.

The general meeting will be opened by the chairman of the board of directors, Hans Peter Bøhn, or a person appointed by the board of directors cf. Section 5-12 of the Norwegian Public Limited Liability Companies Act.

The Company is a public limited company subject to the rules of the Norwegian Public Limited Liability Companies Act. As of the date of this notice, the Company has issued 37,326,390 shares, each of which represents one vote. The shares have equal rights also in all other respects. The Company does not hold own shares as of the date of this notice.

Shareholders and proxy holders who wish to participate at the general meeting are requested to notify the Company of his/her presence by use of the attendance form attached hereto. Shareholders wishing to attend can register online via www.pcibiotech.no(with link to VPS Investor Services) or by sending the attached registration form to:

Nordea Bank Abp, Filial Norge, Issuer Services

Postboks 1166 Sentrum, NO-0107 Oslo

E-post: [email protected]

Shareholders may participate at the general meeting electronically. The Company still encourages shareholders to vote in advance or submit proxies with voting instructions in advance of the general meeting, as further described below. Shareholders who wish to participate electronically must notify the Company of this by e-mail to [email protected]no later than 23 May 2023 at 16:00. Practical information for such participation will be provided to those it concerns before the general meeting.

Shareholders who cannot participate at the general meeting in person may authorise the chairman of the board or another person to vote for their shares by using the proxy form attached hereto. The proxy form may be submitted electronically via VPS Investor Services (www.euronextvps.no), or to Nordea Bank, Issuer Services, or be delivered to the proxy holder and brought to the general

meeting. The proxy must be in writing, dated, signed and submitted no later than at the general meeting. If the shareholder is a company, please attach the shareholder’s certificate of registration to the proxy. Proxy forms, which are sent, are requested sent so that they are received no later than 23 May 2023, 16:00 (CEST). See the enclosed proxy form for further information on proxies.

Shareholders who cannot attend the general meeting may cast votes for each matter on the agenda in advance. Such advance votes must be cast electronically via the Company’s website www.pcibiotech.noor VPS investor services. The deadline for casting advance votes is 23rd May 2023 at 16.00 hours (CEST). Until the deadline, votes already cast may be changed or withdrawn. Votes already cast prior to the general meeting will be considered withdrawn in the event of a shareholder attending the general meeting in person or by proxy.

If shares are registered through a nominee in the VPS register, cf. section 4-10 of the Norwegian Public Limited Liability Companies Act, and the beneficial shareholder wishes to vote for his/her shares, the beneficial shareholder must re-register the shares on a separate VPS account in his/her own name prior to the general meeting. If the holder can prove that such steps have been taken and that the holder has a de facto shareholder interest in the Company, the holder may, in the Company’s opinion, vote for the shares.

Decisions regarding voting rights for shareholders and proxy holders are made by the person opening the meeting, whose decisions may be reversed by the general meeting by simple majority vote.

Shareholders cannot require that new matters are put on the agenda as the deadline for this has lapsed cf. the Norwegian Public Limited Liability Companies Act section 5-11 second sentence. Shareholders have the right to suggest resolutions in matters that are before the general meeting, subject to the limitations of the Norwegian Public Limited Liability Companies Act. Shareholders have the right to be assisted by advisers, and may give one advisor the right to speak.

A shareholder may demand that board members and the chief executive officer provide available information at the general meeting about matters which may affect the assessment of items which have been presented to the shareholders for decision. The same applies to information regarding the Company’s financial position and other business to be transacted at the general meeting, unless the information demanded cannot be disclosed without causing disproportionate harm to the Company.

This notice, other documents regarding matters to be discussed in the general meeting, including the documents to which this notice refers, as well as the Company’s Articles of Association, are available on the Company’s website www.pcibiotech.com. Shareholders may contact the Company by mail, e-mail or telephone in order to request the documents in question on paper. Address: PCI Biotech Holding ASA, Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, 0379 Oslo, Norway, e-mail:[email protected], telephone: +47 67 11 54 00.

The following documents will be available at www.pcibiotech.no:

• This notice and the enclosed form for notice of attendance/proxy
• The board of directors’ proposed resolutions for the Annual General Meeting for the items listed on the agenda
• The recommendation of the Nomination Committee
• The annual accounts and annual report for the financial year 2022, including the Corporate Governance Report for 2022
• The guidelines for remuneration of Executive Management
• Remuneration report 2022 for Executive Management
• Statement from the auditor regarding the Company’s non-distributable equity

Oslo, 4 May 2023,

On behalf of the board of directors of PCI Biotech Holding ASA

Hans Peter Bøhn, Chairman

Appendices: (1) Form of registration and (2) Form of proxy